back to overview


4 Health VCs Share Their Business Priorities and What is Next

July 27, 2020 + Jessica Di Palo
5 Min read

Venture Capital financing in Q1’20 will be the second steepest decline in the past 10 years according to data from CB Insights. Techtour interviewed our Managing Partner Christoph Kausch and 3 other investors to share their business priorities, how they adjusted their strategies and how are they helping their portfolio companies.

Healthtech VCs

Tech Tour: How is the COVID-19 crisis impacting the funding landscape for startups?

Christoph Kausch: Like the rest of us, startups have not been exempt from the impacts of COVID-19. Some have benefited from the increased demand for technological solutions, enabling connectivity in light of social isolation. Other startups – in retail, for example – have clearly suffered. I think the hardest thing for both startups seeking finance, as well as investors, is the current state of uncertainty. There’s a general unwillingness to commit to new investments that aren’t “COVID-proof” right now when we don’t know how long this will all last. Many investors had already felt that startup valuations had been overflowing for some time now. In this respect, there has actually been evidence of better alignment between investors and management teams on finding the best solution to close the deal. There’s enough capital in the market to ensure that the best companies will still get funded. It just may take a bit more time than usual. It’s an obvious consequence that Investment Committees want to see additional diligence and risk assessments for COVID-19. I think it’s also very important now more than ever to support existing portfolio company management teams in their additional funding needs via both grant funding and additional capital injections if needed.

Share the Article

Pioneering the use of machine learning algorithms to turbo-charge drug development

Intelligencia revolutionizes drug development

The psychology of decision making

What makes a good investor?

Revolutionizing medical triage with artificial intelligence

Mediktor's solution for medical triage

MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments

MTIP Fund II is closed!

Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics

Cynerio's new product Cynerio Now!

MTIP invests in Mediktor

New investment in Mediktor

SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right

MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round

MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia

Private Equity 101: Part one – Glossary

Are you new to the healthtech space?

Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey

Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

blog blog blog blog blog blog blog blog blog blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations

MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II

How to pitch to a healthtech Investor

Blog Pitching

MTIP invests in Koa Health to make mental health treatment more accessible

New investment in Koa Health

MTIP scored fantastic grades in the UNPRI assessment report of 2020

UNPRI Report grades 2020


4 Health VCs Share Their Business Priorities and What is Next

Interview Techtour

MTIP invests in Trialbee

New investment in Trialbee

news news news news news news news news news news news news news

TytoCare closes $50 million round as the demand for telehealth accelerates

TytoCare closes new round

The digital healthtech sector is expanding – and so are we!

Two new empolyees start in April

MTIP has sucessfully exited Blueprint Genetics

Blueprint exit January 2020

New MTIP investment in Oviva

New investment in Oviva


Whitepaper: A positive prognosis for the future of healthtech

Our first Whitepaper